The estimated Net Worth of Asha Collins is at least $382 Tysiąc dollars as of 6 May 2024. Asha Collins owns over 257 units of Idexx Laboratories stock worth over $381,913 and over the last 4 years he sold IDXX stock worth over $0. In addition, he makes $0 as Independent Director at Idexx Laboratories.
Asha has made over 2 trades of the Idexx Laboratories stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 257 units of IDXX stock worth $125,997 on 6 May 2024.
The largest trade he's ever made was exercising 344 units of Idexx Laboratories stock on 11 May 2023 worth over $168,649. On average, Asha trades about 55 units every 33 days since 2020. As of 6 May 2024 he still owns at least 779 units of Idexx Laboratories stock.
You can see the complete history of Asha Collins stock trades at the bottom of the page.
Dr. Asha S. Collins serves as Independent Director of the Company. Dr. Collins has served as the Head of U.S. Clinical Operations at Genentech since May 2018. Prior to joining Genentech, Dr. Collins held several senior leadership positions at McKesson Corporation between September 2014 and March 2018, including Vice President of Clinical Sourcing and Business Development from November 2015 to March 2018 and Senior Director, Corporate Strategy and Business Development from September 2014 to November 2015. She was previously Principal Consultant at Quintiles from 2011 to 2014 and Manager at Deloitte Consulting from 2008 to 2011. In July 2019, Dr. Collins was selected as a Health Innovators Fellow by The Aspen Institute. Dr. Collins received her Bachelor of Science degree from the University of Pittsburgh and her PhD in Cancer Biology and Microbiology from the University of Wisconsin-Madison.
Asha's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers oraz Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: